Trial Profile
A randomised, controlled, open-label study of the broader efficacy of atomoxetine hydrochloride in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2006
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms SUNBEAM
- 13 Sep 2006 Status change
- 05 Nov 2005 New trial record.